All 1 tracked stories fall under one category: funding. OPERA Platform is most often covered alongside Korro Bio, which appears in 1 of these 1 story. Their average consequence score of 5 runs below the beat's 6.7 for that window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about OPERA Platform
All 1 tracked stories fall under one category: funding. OPERA Platform is most often covered alongside Korro Bio, which appears in 1 of these 1 story. Their average consequence score of 5 runs below the beat's 6.7 for that window. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window. We currently track 1 Startup story that mention OPERA Platform, all published on March 9, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 43 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering OPERA Platform. Shared-story counts are live from our verified record — not editorial picks.
Korro Bio has announced an oversubscribed $85 million private placement, signaling strong investor confidence in its proprietary RNA editing platform. This capital injection is expected to extend the company's cash runway and accelerate the clinical development of its lead programs targeting genetic diseases.
OPERA Platform is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.